India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot


 

Indian drug maker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday.

The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news. Read More

Comments

Popular posts from this blog

Budgeting Myths Busted: 7 Common Misconceptions Revealed

India to test 100-yr-old vaccine on adults as war on Covid-19 hots up

India Coronavirus Dispatch: Are politicians potential super-spreaders?